TBPH 8-K 2026-09-23
Theravance Biopharma, Inc. (TBPH) 8-K dated 2026-09-23 — accession 0001104659-26-109979.
Theravance Biopharma, Inc. (TBPH) is a biotechnology company listed on NASDAQ.
Theravance Biopharma, Inc. filed a 8-K on 2026-09-23. Accession 0001104659-26-109979.
This 8-K covers: Material agreement (Item 1.01), Acquisition or disposition (Item 2.01), Listing notice (Item 3.01), Change to holders' rights (Item 3.03), Change in control (Item 5.01), Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.
Latest reported TBPH revenue for 2025-12-31 was $107.5M. Net income was $105.9M. Revenue was up 66.9% from 2024-12-31 to 2025-12-31. TBPH currently screens at market cap $861.5M.
Not investment advice. The TBPH SEC hub lists recent forms. The stock page is the research view.